Recombinant MERS-CoV Nucleocapsid His-tag Protein, CF

2 μg/lane of Recombinant MERS-CoV Nucleocapsid His-tag Protein (10521-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 49-55 kDa.

• Reactivity: V
• Format: Carrier-Free

Recombinant MERS-CoV Nucleocapsid His-tag Protein, CF Summary

• Additional Information: Sf21 Insect Cell Expressed, Over 95% Purity
• Details of Functionality: Bioassay data are not available.
• Source: Spodoptera frugiperda, Sf 21 (baculovirus)-derived mers-cov Nucleocapsid protein
  Met1-Thr411, with a C-terminal 6-His tag
• Accession #: YP_007188586.1
• N-terminal Sequence: Sequence has been confirmed by mass spectrometry
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity not tested
• Theoretical MW: 46 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 49-55 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant MERS-CoV Nucleocapsid His-tag Protein, CF

• N Protein
• Nucleocapsid protein
• Nucleocapsid
• ORF9a protein

Background

MERS-CoV, which causes the Middles East Respiratory Syndrome (MERS), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). While the S, E and M proteins build up the viral envelope, the N protein is involved transcription, replication and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (1, 2). The MERS-CoV N protein is a ~45 kDa protein composed of two independent structural domains connected by a linker region. The N-terminal region contains an Intrinsically Disordered Region (3) and an RNA binding domain (4), the linker region interacts with the M protein and the C-terminal region contains a self-association domain (1, 2). The MERS-CoV N protein shares 46.3% and 4.5% amino acid sequence identity with SARS-CoV-1 and SARS-CoV-2 N protein, respectively. MERS-CoV N proteins have been shown to inhibit Type I Interferon(IFN) production(1). In addition, the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity, making it a promising therapeutic target (5-7).

1. Li, Y. et al. (2019) Engineering. 5:940.
2. Hurst, K. R. et al. (2009) J. Virol. 83:7221.
3. Wang, Y. et al. (2015) Acta. Crystallogr. F. Struct. Biol. Commun. 71:977.
4. Papageorgiou, N. et al. (2016) Acta. Crystallogr. D. Struct. Biol. 72:192.
5. Che, X. Y. et al. (2004) J. Clin. Microbiol. 42:2629.
6. Guan, M. et al. (2004) Clin. Diagn. Lab. Immunol. 11:287.
7. Chang, C-K. et al.(2016) Drug Discov. Today. 21:562.

Bioinformatics

• Uniprot:
  • YP_007188586.1()